Start here if you're new
what it is
IFF makes the flavors, scents, and ingredient systems buried inside your food, drinks, cosmetics, and pills.
how it gets paid
Last year L Flavors & Frag made $10.9B in revenue. Nourish was the main engine at $5.6B, or 51% of sales.
why it's growing
Revenue grew 94.2% last year. In all, we look for earnings per share to advance another 2% this year, while sales rebound around 3%.
what just happened
The latest quarter was ugly: EPS came in at $0.08 versus $1.00 expected, a 92.0% miss.
At a glance
B++ balance sheet — above average — nothing keeping you up at night
75/100 earnings predictability — reasonably predictable
17.1x trailing p/e — the market's not buying it — or you found a deal
2.1% dividend yield — cash in your pocket every quarter
5.5% return on capital — nothing to write home about
xvary composite: 59/100 — below average
What they do
IFF makes the flavors, scents, and ingredient systems buried inside your food, drinks, cosmetics, and pills.
IFF sits deep inside customer formulas, and 72% of 2024 sales came from outside the U.S. That global reach matters when your toothpaste, soda, and supplements need the same smell and taste every time. R&D was 5.8% of sales in 2024, which means the company keeps spending to stay inside your daily products.
How they make money
$10.9B
annual revenue · their business grew +94.2% last year
Nourish
$5.6B
Health & Biosciences
$2.2B
Scent
$2.3B
Pharma Solutions
$0.9B
The products that matter
flavors and fragrance ingredients
Ingredients Platform
$10.9B revenue
it's the core $10.9B business, and the key question is not demand alone. it's whether that scale can earn better than a 6.0% return on capital.
core platform
Key numbers
3.5%
operating margin
Operating margin → profit from the core business before interest and taxes → so what: the core machine is still losing money.
$4.7B
long-term debt
Long-term debt → money owed over many years → so what: the balance sheet has weight while the turnaround is still unfinished.
72%
international sales
International sales → revenue from outside the U.S. → so what: IFF is globally diversified, but also tied to currency and macro swings.
17.1x
trailing p/e
P/E → stock price divided by past earnings → so what: you are not buying a busted penny stock, even with weak margins.
Financial health
B++
strength
- balance sheet grade B++ — above average financial health
- risk rank 3 — safer than 50% of stocks
- price stability 65 / 100
- long-term debt $4.7B (20% of capital)
- net profit margin 10.0% — keeps 10 cents of every dollar in revenue
- return on equity 6% — $0.06 profit for every $1 investors have put in
B++ — functional but not a standout on the balance sheet.
Total return vs. market
You invested $10,000 in IFF 3 years ago → it's now worth $8,940.
The index would have given you $13,880.
source: institutional data · total return
What just happened
missed estimates
The latest quarter was ugly: EPS came in at $0.08 versus $1.00 expected, a 92.0% miss.
Revenue was $8.3B, while another verified revenue source shows TTM revenue of $10.9B and a 5.2% yearly decline. The clean takeaway is that profit quality remains the real problem.
$2.7B
revenue
$0.08
eps
36.7%
gross margin
the number that mattered
The 92.0% EPS miss matters most because it tells you the turnaround is still fragile, even with management talking about operating progress.
-
international flavors & fragrances (iff) should make decent operating progress this year.
-
the company likely recorded mixed results in 2025. (full year results were scheduled to be released shortly after we went to press with this report.) recent divestitures and tougher operating conditions have weighed on the top line over the past few quarters, likely causing sales to slip 5% for the full year.
-
management’s realignment efforts (discussed below), however, probably aided profits, enabling the bottom line to advance 2% in 2025.even though the company’s food ingredients business had been struggling of late, gains from iff’s taste, health & biosciences, and scent segments helped offset some of the negative impact. looking ahead, we assume macroeconomic headwinds from geopolitical tensions and market uncertainty will continue to abate.
-
ongoing business improvements should also bolster profits in the near term.
-
in all, we look for earnings per share to advance another 2% this year, while sales rebound around 3%.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the top threat is turnaround execution after divestitures and portfolio realignment.
med
turnaround needs to show up in earnings, not just language
IFF finished FY2025 at $4.40 in EPS, and the current setup points to only modest improvement from there. if cost cuts and simplification do not move earnings meaningfully above that base, the thesis stalls.
this risk directly hits the valuation case built on $4.40–$4.50 earnings power.
med
portfolio cleanup can shrink the top line before it improves quality
the current page already says recent divestitures and tougher operating conditions weighed on sales. if the expected rebound of around 3% does not appear, investors are left with a $10.9B platform that is merely getting smaller and cleaner.
this exposes the full revenue base because the debate is whether $10.9B becomes a healthier business or just a leaner one.
med
debt is manageable, but it limits patience
$4.7B of long-term debt and 20% of capital is not distress territory. it does mean management has less room to let a slow fix drag on forever.
if profitability stays ordinary at a 6.0% return on capital, balance-sheet flexibility matters more.
IFF is not a binary story. it is a proof story: can a $10.9B platform earn better returns without leaning on narrative alone.
source: institutional data · regulatory filings · risk analysis
Pay attention to
metric
EPS moves above the $4.40 floor
the turnaround story gets more credible if earnings push past FY2025's $4.40 and clear the $4.50 estimate.
trend
sales actually rebound from the $10.9B base
the current setup calls for roughly 3% sales improvement. if that does not show up, this remains a cost-cut story.
risk
return on capital stays stuck at 6.0%
revenue growth gets the headlines. return on capital tells you whether management is fixing the business or just resizing it.
calendar
next earnings for proof on realignment
the next report needs to connect portfolio changes, margins, and the promised operating progress in one place.
Analyst rankings
short-term outlook
average
momentum score 3. in human-speak, analysts see a stock acting mostly like the market rather than breaking away from it.
risk profile
average
stability score 3 means typical risk for a large-cap name. not a bunker stock, not a chaos machine.
chart momentum
bottom 5%
technical score 5 is the weakest reading here. the chart is telling you this story still has skeptics.
earnings predictability
75 / 100
guidance is reasonably dependable. that makes future misses more meaningful, not less.
source: institutional data
Institutional activity
343 buyers vs. 325 sellers in 3q2025. total institutional holdings: 0.2B shares.
source: institutional data
Price targets
3-5 year target range
$61
$104
$75
current price
$83
target midpoint · +10% from current · 3-5yr high: $130 (+75% · 17% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive